WebMD

Evrysdi for Spinal Muscular Atrophy: What You Need to Know

Evrysdi, also known as risdiplam, is an oral medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...
Business Wire

New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi ® (risdiplam) in a broad range of ...
Business Wire

New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

– Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 seconds – – Evrysdi has proven efficacy in ...
Healio

Evrysdi linked to significantly improved outcomes in spinal muscular atrophy at 5 years

Please provide your email address to receive an email when new articles are posted on . At 5 years, 91% of pediatric patients treated with Evrysdi were alive, 81% without permanent ventilation. Data ...
Monthly Prescribing Reference

New Tablet Formulation of SMA Therapy Evrysdi Gets FDA Approval

Credit: Genentech. The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water. Each Evrysdi tablet contains 5mg of risdiplam and is suitable ...
Nasdaq

New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With ...

– Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years with SMA who received prior treatment, showed a consistent safety profile and >2-fold increase in SMN protein levels – ...
Monthly Prescribing Reference

Evrysdi Use Extended to Infants Younger Than 2 Months With Spinal Muscular Atrophy

The approval was based on efficacy and safety data from the phase 2 RAINBOWFISH study, which included presymptomatic infants aged from birth to 6 weeks old with genetically diagnosed SMA. The Food and ...
Nasdaq

New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

Basel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term ...